Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

As global markets navigate a busy earnings season with mixed signals from economic data, major indices like the Nasdaq Composite and S&P MidCap 400 have experienced volatility, highlighting investor ...

In such an environment, identifying high growth tech stocks like ALTEOGEN can be crucial for investors seeking to capitalize on robust earnings potential and long-term growth prospects.

Name Insider Ownership Earnings Growth People & Technology (KOSDAQ:A137400) 16.4% 35.6% Seojin SystemLtd (KOSDAQ:A178320) 30.8% 49.1% Overview: ALTEOGEN Inc. is a biotechnology company specializing in ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...